Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 206

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 206
---
 Kadimastem. Inflation, which increased significantly during 2024, could adversely affect Kadimastem’s business by increasing the costs of raw material and labor needed to operate its business and could continue to adversely affect Kadimastem in future periods. If this current inflationary environment continues, there can be no assurance that Kadimastem would be able to recover related cost increases through price increases, which could result in downward pressure on Kadimastem’s operating margins. As a result, Kadimastem’s financial condition, results of operations, and cash flows could be adversely affected over time. Kadimastem may fail to realize some or all of the anticipated benefits of the proposed Merger, which may adversely affect the value of each Kadimastem Ordinary Share. The success of the Merger will depend, in part, on Kadimastem’s ability to realize the anticipated benefits from combining Kadimastem and NLS. However, to realize these anticipated benefits, the businesses of Kadimastem and NLS must be successfully combined and the two companies’ respective operations, technologies and personnel must be integrated following the Closing. If Kadimastem is not able to achieve these objectives within the anticipated time frame, or at all, the anticipated benefits and cost savings of the Merger may not be realized fully or at all or may take longer to realize than expected and the value of Kadimastem Ordinary Shares may be adversely affected. In addition, the overall integration of the businesses is a complex, time -consumingand expensive process that, without proper planning and effective and timely implementation, could significantly disrupt Kadimastem’s operations following closing. Specifically, risks in integrating NLS into Kadimastem’s operations to realize the anticipated benefits of the Merger include, among other things, the failure to: •effectively coordinate efforts to communicate Kadimastem’s capabilities and products following closing; •compete effectively for additional opportunities expected to be available to Kadimastem following closing; •integrate and harmonize financial reporting and information technology systems of Kadimastem and NLS; 70 •retain Kadimastem’s relationships with its customers and successfully integrate NLS into these existing relationships; •integrate NLS and Kadimastem executive officers’ teams; •retain and integrate key NLS and Kadimastem employees; •successfully address Kadimastem’s existing liabilities; •coordinate operations across time zones, continents and cultures; •manage the diversion of management’s